Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis is attractive because its NeXT Personal MRD test is gaining clinical traction, with Q1'26 volume of 7,815 tests up 258% Y/Y and more than 1,000 oncologists ordering it, while Medicare coverage wins in breast cancer, lung cancer, and pan-cancer IO monitoring are helping de-risk adoption. The company also has a valuable pharma services franchise, with Q1'26 pharma revenue of $10.7M and a broader biopharma MRD business tracking to about $20M in 2026, reinforcing its role in personalized cancer vaccine sequencing and analytics. Even with margin pressure from commercialization, the strategic combination with Tempus should unlock full salesforce coverage, improve reimbursement economics, and support much stronger growth across diagnostics, data, and vaccine-related services.

Personalis is viewed negatively because the stock now trades very close to the announced $16.25 deal value, leaving little upside while Tempus is expected to close the acquisition over the coming months and no higher bidder is anticipated. The bear case highlights fundamental business risks: MRD reimbursement from Medicare or commercial payers could disappoint, biopharma order timing and budgets can remain volatile quarter to quarter, and demand from large pharma for personalized cancer vaccine development may soften. Although the process was competitive and there are multiple revenue streams tied to sequencing and analytics, the risk/reward has deteriorated as the market has largely priced in the transaction while deal-closing risk still lingers.